|
18 Apr 2023 |
OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio
|
|
18 Apr 2023 |
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
|
|
18 Apr 2023 |
Alligator Bioscience Announces Poster Presentation on ATOR-4066 at the AACR Annual Meeting 2023
|
|
17 Apr 2023 |
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
|
|
17 Apr 2023 |
Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023
|
|
17 Apr 2023 |
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting
|
|
17 Apr 2023 |
ZielBio to Present New Research on the Utility of Cancer-Specific Plectin (CSP) and ZB131 in Antibody-Drug Conjugates at AACR Annual Meeting 2023
|
|
17 Apr 2023 |
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023
|
|
17 Apr 2023 |
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
|
|
17 Apr 2023 |
Lassen Therapeutics Presents Data Demonstrating Anti-IL18 Binding Protein Antibody Efficacy and Enhancement of Anti-Tumor Immunity at AACR Annual Meeting
|
|
17 Apr 2023 |
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
|
|
17 Apr 2023 |
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
|
|
17 Apr 2023 |
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
|
|
17 Apr 2023 |
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
|
|
17 Apr 2023 |
Imfinzi-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial
|
|
17 Apr 2023 |
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
|
|
17 Apr 2023 |
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
|
|
17 Apr 2023 |
Faron Pharmaceuticals Announces BEXMAB Study Update
|
|
15 Apr 2023 |
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
|
|
14 Apr 2023 |
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
|
|
14 Apr 2023 |
Harbour BioMed Announces Results of Phase Ib Clinical Trial of Porustobart in Combination with Toripalimab in Advanced High-Grade Neuroendocrine Neoplasms at AACR Annual Meeting
|
|
14 Apr 2023 |
TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics
|
|
14 Apr 2023 |
Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare
|
|
14 Apr 2023 |
U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab
|
|
13 Apr 2023 |
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
|
